Effects of acute administration of the Phenothiazinium Chromophore Methylene blue during life threatening cyanide intoxication

在危及生命的氰化物中毒期间急性施用吩噻嗪发色团亚甲蓝的影响

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT Cyanide, a very toxic mitochondrial poison, has a wide spread usage in various industrial activities. It is present in many synthetic materials and can be released in gaseous form during a house fire. Since CN can be easily weaponized, it is considered as a serious threat for the civilian population. The treatment of acute CN intoxication relies on (1) specific antidotes, to decrease the concentration of CN in the blood and tissues, and (2) symptomatic treatments, essential at the early stage of exposure, consisting in an aggressive ventilatory and circulatory support, akin to the treatment of any conditions associated with cardio-respiratory depression. We have recently found that the phenothiazinium chromophore methylene blue (MB), which can counteract the toxicity of various mitochondrial poisons (hydrogen sulfide and Azure B), can also oppose CN- induced acute circulatory failure. The mechanisms of action of MB as well as the limits of its efficacy, following CN intoxication, remain to be determined. The objective of our proposal is first to validate our preliminary observations and to determine the interest of the use of MB during and following CN intoxication induced coma and cardiac failure in the rat. We will determine if MB can improve the immediate and long-term outcome of CN intoxication when used alone and more importantly as an adjuvant of antidotes already approved for the treatment of CN intoxication. Second, we will explore the potential mechanisms of action of MB, using isolated contracting cardiomyocytes intoxicated with CN. These studies will be performed in collaboration with the group of Dr. Joseph Cheung, Temple University. Since MB has been used for decades for treating methemoglobinemia (1-2 mg/kg iv) in humans, our goal is to reposition methylene blue, a drug already on the WHO's list of essential medications, as a treatment of CN intoxication.
项目总结/摘要 氰化物是一种毒性很强的线粒体毒物,广泛应用于各种工业生产中。是 存在于许多合成材料中,并且可以在房屋火灾期间以气体形式释放。由于CN可以 它很容易制成武器,被认为是对平民的严重威胁。急性CN的治疗 中毒依赖于(1)特定解毒剂,以降低血液和组织中氯化萘的浓度, (2)对症治疗,在暴露的早期阶段至关重要,包括积极的治疗, 和循环支持,类似于治疗任何与心肺抑制相关的疾病。 我们最近发现吩噻嗪生色团亚甲基蓝(MB), 抵消各种线粒体毒物(硫化氢和天青B)的毒性,也可以对抗CN- 导致急性循环衰竭。MB的作用机制及其有效性限度,如下 氯化萘中毒,仍有待确定。 我们建议的目的是首先验证我们的初步观察结果, 在大鼠CN中毒诱导昏迷和心力衰竭期间和之后使用MB的兴趣。我们 将确定MB单独使用时是否可改善CN中毒的即刻和长期结局 更重要的是作为已批准用于治疗CN中毒的解毒剂的佐剂。 其次,我们将探索MB的潜在作用机制,使用分离的收缩心肌细胞 用CN麻醉这些研究将与Joseph Cheung博士的团队合作进行, 天普大学。 由于MB已被用于治疗人类高铁血红蛋白血症(1-2 mg/kg iv)数十年,我们的研究表明, 目标是重新定位亚甲蓝,一种已经在世界卫生组织基本药物清单上的药物,作为一种治疗方法 CN中毒

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Circulatory Failure During Noninhaled Forms of Cyanide Intoxication.
  • DOI:
    10.1097/shk.0000000000000732
  • 发表时间:
    2017-03
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Haouzi P;Tubbs N;Rannals MD;Judenherc-Haouzi A;Cabell LA;McDonough JA;Sonobe T
  • 通讯作者:
    Sonobe T
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Philippe A Haouzi其他文献

Philippe A Haouzi的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Philippe A Haouzi', 18)}}的其他基金

Restoring The Mechanical Properties of the Respiratory System as a Treatment of Fentanyl Overdose-Induced Hypoventilation using Kappa Agonists
使用 Kappa 激动剂恢复呼吸系统的机械特性来治疗芬太尼过量引起的通气不足
  • 批准号:
    10766378
  • 财政年份:
    2022
  • 资助金额:
    $ 19.45万
  • 项目类别:
Restoring The Mechanical Properties of the Respiratory System as a Treatment of Fentanyl Overdose-Induced Hypoventilation using Kappa Agonists
使用 Kappa 激动剂恢复呼吸系统的机械特性来治疗芬太尼过量引起的通气不足
  • 批准号:
    10410611
  • 财政年份:
    2022
  • 资助金额:
    $ 19.45万
  • 项目类别:
Treatment of Fentanyl Overdose-Induced Respiratory Failure by Low-Dose Dexmedetomidine
小剂量右美托咪定治疗芬太尼过量所致呼吸衰竭
  • 批准号:
    10828679
  • 财政年份:
    2020
  • 资助金额:
    $ 19.45万
  • 项目类别:
Treatment of Fentanyl Overdose-Induced Respiratory Failure by Low-Dose Dexmedetomidine
小剂量右美托咪定治疗芬太尼过量所致呼吸衰竭
  • 批准号:
    10595421
  • 财政年份:
    2020
  • 资助金额:
    $ 19.45万
  • 项目类别:
Treatment of Fentanyl Overdose-Induced Respiratory Failure by Low-Dose Dexmedetomidine
小剂量右美托咪定治疗芬太尼过量所致呼吸衰竭
  • 批准号:
    10701905
  • 财政年份:
    2020
  • 资助金额:
    $ 19.45万
  • 项目类别:
The cyclic redox dye Azure B as a novel cyanide antidote: in vivo efficacy studies
环状氧化还原染料 Azure B 作为新型氰化物解毒剂:体内功效研究
  • 批准号:
    10223544
  • 财政年份:
    2019
  • 资助金额:
    $ 19.45万
  • 项目类别:
Methylene blue as an antidote against hydrogen sulfide intoxication
亚甲蓝作为硫化氢中毒的解毒剂
  • 批准号:
    9324057
  • 财政年份:
    2016
  • 资助金额:
    $ 19.45万
  • 项目类别:
Methylene blue as an antidote against hydrogen sulfide intoxication
亚甲蓝作为硫化氢中毒的解毒剂
  • 批准号:
    9144894
  • 财政年份:
    2016
  • 资助金额:
    $ 19.45万
  • 项目类别:
Methylene Blue, A Novel Treatment of H2S Poisoning-induced Brain Injury
亚甲蓝,一种治疗硫化氢中毒脑损伤的新方法
  • 批准号:
    8796074
  • 财政年份:
    2014
  • 资助金额:
    $ 19.45万
  • 项目类别:
Crystalline hydroxocobalamin and methemoglobin as a treatment of H2S intoxication
结晶羟钴胺和高铁血红蛋白治疗 H2S 中毒
  • 批准号:
    8551778
  • 财政年份:
    2012
  • 资助金额:
    $ 19.45万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 19.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了